Lactobacillus salivarius
EVIDENCE: MODERATEAlso sold as: L. salivarius, Ligilactobacillus salivarius, L. salivarius WB21, WB21
Live L. salivarius WB21 tablets have human trials measuring reduced breath-odor compounds and periodontal bacteria at about two billion CFU daily. Inactivated bacteria are a different preparation; the live-strain trials do not establish their effects.
Compiled by iSupplementReviews editorial team ·Updated 2026-10-06 · 6 sources
- Type
- Probiotic — oral/GI species
- Studied dose
- ~2.0×10⁹ CFU/day live bacteria (WB21), oral tablets/lozenges/oil drops, 2–8 weeks
- Best form
- Named live strain with CFU count (WB21 is the studied oral strain) — species alone doesn't guarantee the studied organism
- Our rating
- MODERATE — Several human trials — limits in size, duration, or independence
What is Lactobacillus salivarius?
L. salivarius, now Ligilactobacillus salivarius, occurs in the gut and mouth and can produce antimicrobial compounds. Oral trials mainly concern WB21, delivered live in tablets or oil drops held in the mouth.
Other names and forms it’s sold as
- WB21: the strain with the human oral trial cluster (tablets ~2×10⁹ CFU/day, lozenges, oil drops)
- Generic “L. salivarius” in proprietary blends: strain unnamed, dose unstated; can’t be matched to the trials
- Postbiotic/inactivated forms: dead cells or culture supernatants marketed as delivering the same effect without live organisms; essentially untested in human oral studies
What is it claimed to do?
Reduce bad-breath compounds, suppress periodontal pathogens, rebalance the oral microbiome, and protect gums. The first two have real human data for WB21; the latter two are extrapolations.
What does the research show?
| Claim | Evidence | Dose studied | Verdict |
|---|---|---|---|
| Reduced volatile sulfur compounds (bad breath) | 14-day double-blind crossover trial: VSCs and pocket depth fell vs placebo | 2×10⁹ CFU/day | Supported (WB21) — modest, subjective scores improved on placebo too |
| Lower periodontopathic bacteria | Trials found subgingival T. forsythia and the 5-pathogen sum reduced at 4–8 weeks | 2×10⁹ CFU/day | Supported (WB21) — microbiological outcome |
| Less bleeding on probing | Pilot + oil-drop trial showed improvement vs placebo | 2×10⁹ CFU/day | Supported (WB21) — secondary outcome |
| Oral microbiome “rebalance” | Trials measured pathogen counts, not durable community restructure | — | Plausible — no long-term colonization shown |
| Same effects from a dead/postbiotic form | No human oral trials | — | Unproven |
The live-vs-postbiotic gap
Everything documented about L. salivarius in the mouth comes from live organisms arriving at ~2 billion CFU/day: organisms that transiently colonize saliva and secrete salivaricin where the bacteria live. A “postbiotic” presentation (inactivated cells or their metabolites) removes the colonization step and freezes whatever compounds survive processing. That may still be antimicrobial (cell-free supernatant inhibited pathogens in lab work) but it is a hypothesis, not a tested product. When a label says “L. salivarius” without strain or CFU, you can’t even tell which product concept you’re buying.
What dose was studied?
| Goal | Dose | Form/route | Duration |
|---|---|---|---|
| Malodor / VSC reduction | 2.0×10⁹ CFU/day | WB21 tablet + xylitol | 14 days |
| Periodontopathic bacteria | 2.01×10⁹ CFU/day | WB21 tablet | 4–8 weeks |
| Bleeding on probing | WB21 oil drops held in mouth | 2 weeks | 2 weeks |
Side effects
Well tolerated in trials. The lactobacillus class carries rare bloodstream-infection reports in severely immunocompromised or critically ill patients: the standard live-probiotic caution. GI adjustment in the first days is the usual consumer-level effect.
Drug interactions
No meaningful interactions documented. Antibiotics will kill live probiotic doses; spacing doses away from antibiotic courses is standard advice.
Who should not take it?
Severely immunocompromised patients (live-probiotic caution); anyone on immunosuppression post-transplant or with central lines should clear probiotics with their physician. Pregnancy/nursing: lactobacilli are common in foods but supplement-level CFU hasn’t been specifically studied, so the standard “ask first” applies.
What the authorities say
No regulator has evaluated L. salivarius for oral health claims: no FDA monograph, no EMA/NCCIH assessment. It sits in the general probiotic supplement space: legal to sell, claims unverified by institutions.
What to know about L. salivarius
WB21 has human oral research at about two billion live bacteria daily. The measured benefits were modest and concerned breath compounds and periodontal bacteria. Unnamed strains, undisclosed counts, and inactivated preparations do not automatically share those findings.
Frequently asked questions about Lactobacillus salivarius
Does L. salivarius help bad breath?
For the WB21 strain, there's real (if modest) evidence: a 14-day double-blind crossover trial found volatile sulfur compound concentrations and probing pocket depth fell versus placebo at 2×10⁹ CFU/day, and a pilot trial showed breath scores improving at 2–4 weeks. The subjective smell score improved under placebo too, a reminder that expectation effects are strong in breath studies.
Does L. salivarius help gums?
The WB21 trials found reductions in subgingival periodontal pathogens (notably Tannerella forsythia) and bleeding-on-probing versus placebo at 2–8 weeks. These are microbiological and secondary-clinical outcomes: 'healthier gum flora,' not reversal of periodontal disease.
How is L. salivarius supposed to work in the mouth?
Two documented mechanisms: it produces salivaricin, an antimicrobial peptide that inhibits Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, and Streptococcus mutans in co-culture; and it transiently colonizes saliva (WB21 DNA was detectable in volunteers' saliva within two weeks of daily tablets).
Is a 'postbiotic' L. salivarius the same thing?
No, and this is the gap that matters. Every human oral trial used live bacteria (~2 billion CFU/day); the proposed benefits depend on an organism that arrives alive, transiently colonizes, and secretes antimicrobial peptides in the mouth. A heat-killed or metabolite-only 'postbiotic' form has essentially no published human oral trials; it's a plausible hypothesis, not an evidence match.
Is L. salivarius safe?
In trials it's been well tolerated; the lactobacilli as a class carry rare bloodstream-infection reports in severely immunocompromised or critically ill patients, so that population is generally advised to avoid live probiotic supplements. Postbiotic forms don't carry that live-organism risk but are unstudied for benefit.
References
- [1]L. salivarius WB21 tablets improved periodontal condition — randomized, double-blind, placebo-controlled (J Clin Periodontol 2008)
- [2]Orally administered L. salivarius WB21 tablets reduced periodontopathic bacteria — double-blind RCT (J Clin Periodontol 2009)
- [3]L. salivarius WB21 tablets for oral malodor — double-blind, randomized, placebo-controlled crossover trial (2014)
- [4]L. salivarius WB21 on halitosis and oral health — open-label pilot (2010)
- [5]WB21 oil drops on periodontal health and VSC-producing microbiota (J Breath Res 2012)
- [6]Salivaricin-mediated inhibition of periodontopathogens by L. salivarius WB21 (J Dent Rehabil Appl Sci 2025)
Products we reviewed containing Lactobacillus salivarius
Based on recorded labels or seller-described formulas. Inclusion does not establish a match to the strains, preparations or amounts studied here; check each review's disclosure limits.